SignalFDA/Bio

Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Stu

Positive Phase 3 mosliciguat results and ongoing PHrontier study drive high biotech relevance.

What changed

Positive Phase 3 mosliciguat results and ongoing PHrontier study drive high biotech relevance.

Why it matters

Positive Phase 3 mosliciguat results and ongoing PHrontier study drive high biotech relevance. — impact context not separately stored; see What changed.

Sources

eodhd